




RealRate

# MEDICINAL PRODUCTS 2017

Oncocyte Corp  
Rank 33 of 44

ONCOCYTE™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Oncocyte Corp is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -31%, being 16% points above the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	12,696
Assets, Non-Current	0
General and Administrative Expense	5,463
Goodwill	988
Liabilities, Current	4,275
Liabilities, Non-Current	0
Other Assets	75
Other Compr. Net Income	-304
Other Expenses	0
Other Liabilities	310
Other Net Income	-28
Other Revenues	0
Property, Plant and Equipment, Net	688
Research and Development	5,677

Output Variable	Value in 1000 USD
Liabilities	4,585
Assets	14,447
Expenses	11,140
Revenues	0
Stockholders Equity	9,862
Net Income	-11,168
Comprehensive Net Income	-11,320
Economic Capital Ratio	-31%